News
Breega donates €125,000 to support research on Lou Gehrig’s disease (ALS)
Breega, a venture capital fund created by entrepreneurs for entrepreneurs, finances technology start-ups in Europe and Africa. Breega raised its first fund in 2015 and now has over €700 million in assets under management and has financed over 120 start-ups.
Breega is one of the few French funds with B Corp certification, reflecting a structured approach to social, environmental and governance issues.
Since its creation, Breega has been committed to fighting ALS by providing financial support for medical research.
Our role as an investor goes beyond financial performance: it must serve society. This year, thanks to the sale of one of our holdings, a company that has helped more than 50,000 people who were far from the job market find work, we are able to contribute €125,000 to the ICM’s research efforts, particularly in the fight against ALS, a cause we have been committed to since our inception.
emphasises Maximilien Bacot, co-founder of Breega.
Many thanks to Breega for this valuable support, which strengthens our work and makes a tangible contribution to advancing research into ALS, a neurodegenerative disease that is still incurable.
